Wheatland Advisors Inc. decreased its stake in Shire PLC (NASDAQ:SHPG) by 3.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,958 shares of the biopharmaceutical company’s stock after selling 161 shares during the period. Wheatland Advisors Inc.’s holdings in Shire PLC were worth $819,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Summit Financial Group Inc. acquired a new stake in Shire PLC during the second quarter valued at $275,000. Pioneer Investment Management Inc. raised its stake in Shire PLC by 331.2% in the second quarter. Pioneer Investment Management Inc. now owns 67,699 shares of the biopharmaceutical company’s stock valued at $11,189,000 after buying an additional 52,000 shares during the period. Pictet Asset Management Ltd. raised its stake in Shire PLC by 10.3% in the second quarter. Pictet Asset Management Ltd. now owns 455,908 shares of the biopharmaceutical company’s stock valued at $78,744,000 after buying an additional 42,466 shares during the period. Goelzer Investment Management Inc. raised its stake in Shire PLC by 1.6% in the second quarter. Goelzer Investment Management Inc. now owns 22,534 shares of the biopharmaceutical company’s stock valued at $3,724,000 after buying an additional 351 shares during the period. Finally, Hartford Financial Management Inc. raised its stake in Shire PLC by 5.4% in the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 32 shares during the period. Hedge funds and other institutional investors own 21.04% of the company’s stock.

Shire PLC (SHPG) opened at 153.87 on Thursday. The stock’s 50 day moving average is $165.41 and its 200-day moving average is $172.82. Shire PLC has a 12-month low of $153.43 and a 12-month high of $209.22. The company has a market cap of $45.83 billion, a P/E ratio of 157.82 and a beta of 1.60.

Shire PLC (NASDAQ:SHPG) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.53 by $0.20. The company had revenue of $3.75 billion during the quarter. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. The firm’s quarterly revenue was up 54.2% compared to the same quarter last year. During the same quarter last year, the company earned $3.38 EPS. Analysts predict that Shire PLC will post $14.92 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Wheatland Advisors Inc. Decreases Stake in Shire PLC (SHPG)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/10/wheatland-advisors-inc-decreases-stake-in-shire-plc-shpg.html.

Several equities research analysts recently weighed in on the stock. Jefferies Group LLC reiterated a “hold” rating and set a $206.00 price objective (down previously from $216.00) on shares of Shire PLC in a research note on Wednesday. Zacks Investment Research upgraded shares of Shire PLC from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub lowered shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Royal Bank Of Canada set a $213.00 price target on shares of Shire PLC and gave the company a “buy” rating in a research note on Friday, August 4th. Finally, Piper Jaffray Companies set a $159.00 price target on shares of Shire PLC and gave the company a “hold” rating in a research note on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $222.27.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.